ES2609912T3 - Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 - Google Patents

Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 Download PDF

Info

Publication number
ES2609912T3
ES2609912T3 ES08771748.4T ES08771748T ES2609912T3 ES 2609912 T3 ES2609912 T3 ES 2609912T3 ES 08771748 T ES08771748 T ES 08771748T ES 2609912 T3 ES2609912 T3 ES 2609912T3
Authority
ES
Spain
Prior art keywords
continued
trpa1
dioxo
alkyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08771748.4T
Other languages
English (en)
Spanish (es)
Inventor
Howard Ng
Manfred Weigele
Magdalene Moran
Jayhong Chong
Christopher Fanger
Glenn R. Larsen
Donato Del Camino
Neil Hayward
Steven P. Adams
Amy Ripka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hydra Biosciences LLC
Original Assignee
Hydra Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences LLC filed Critical Hydra Biosciences LLC
Application granted granted Critical
Publication of ES2609912T3 publication Critical patent/ES2609912T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES08771748.4T 2007-06-22 2008-06-23 Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1 Active ES2609912T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94584007P 2007-06-22 2007-06-22
US94586607P 2007-06-22 2007-06-22
US945866P 2007-06-22
US945840P 2007-06-22
PCT/US2008/067901 WO2009002933A1 (en) 2007-06-22 2008-06-23 Methods and compositions for treating disorders

Publications (1)

Publication Number Publication Date
ES2609912T3 true ES2609912T3 (es) 2017-04-25

Family

ID=40186010

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08771748.4T Active ES2609912T3 (es) 2007-06-22 2008-06-23 Compuestos de 2,6-dioxo, -2,3-dihidro-1h-purina útiles para el tratamiento de trastornos relacionados con la actividad del canal trpa1

Country Status (11)

Country Link
US (3) US8163761B2 (enExample)
EP (3) EP2170309B1 (enExample)
JP (5) JP2010530901A (enExample)
CN (4) CN101801362B (enExample)
AU (1) AU2008268463B2 (enExample)
CA (2) CA2962043A1 (enExample)
DK (1) DK2170309T3 (enExample)
ES (1) ES2609912T3 (enExample)
HR (1) HRP20200357T1 (enExample)
SI (1) SI3184527T1 (enExample)
WO (1) WO2009002933A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
WO2010039289A2 (en) 2008-05-14 2010-04-08 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
US7951814B2 (en) 2008-06-17 2011-05-31 Glenmark Pharmaceuticals, S.A. Quinazolinedione derivatives as TRPA1 modulators
WO2010077976A2 (en) 2008-12-17 2010-07-08 The Regents Of The University Of California Prokineticin receptor antagonists and uses thereof
US8362025B2 (en) * 2008-12-22 2013-01-29 Hydra Biosciences, Inc. Compositions useful for treating disorders related to TRPA1
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
US8623880B2 (en) 2009-03-23 2014-01-07 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as TRPA1 modulators
BRPI1009372A2 (pt) * 2009-03-23 2016-05-31 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica e respectivos usos
ES2456515T3 (es) * 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
KR20120049940A (ko) * 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
KR101591153B1 (ko) 2010-12-20 2016-02-02 그렌마크 파머수티칼스 에스. 아. Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
WO2012098281A2 (es) 2011-01-19 2012-07-26 Universidad Miguel Hernández De Elche Péptidos moduladores de receptores trp y sus usos
RU2014100744A (ru) 2011-06-13 2015-07-20 Гленмарк Фармасьютикалс С.А. Лечение респираторных нарушений с помощью trpa1 антагонистов
JP2014517062A (ja) 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
US20140148423A1 (en) * 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
KR20140073496A (ko) 2011-08-09 2014-06-16 하이드라 바이오사이언시스, 인코포레이티드 일과성 수용체 잠재 이온채널 trpa1의 억제
US20140364445A1 (en) 2011-12-05 2014-12-11 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
US9962430B2 (en) 2012-02-15 2018-05-08 Chirhoclin, Inc. Methods for treating pain associated with chronic pancreatitis
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
US11406718B2 (en) 2012-05-29 2022-08-09 Chirhoclin, Inc. Methods of detecting pancreobiliary ductal leaks
US9221821B2 (en) 2012-06-05 2015-12-29 Forest Laboratories Holdings, Limited Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
AU2013273118B2 (en) * 2012-06-08 2015-11-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
US20140163048A1 (en) * 2012-08-09 2014-06-12 Cubist Pharmaceuticals, Inc. Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
JP6306607B2 (ja) * 2012-12-21 2018-04-04 ケモセントリックス，インコーポレイティド ジアゾールアミド
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
WO2014113671A1 (en) * 2013-01-18 2014-07-24 Cubist Pharmaceuticals, Inc. Inhibiting the transient receptor potential a1 ion channel
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
MX2016004741A (es) 2013-10-15 2016-07-26 Glenmark Pharmaceuticals Sa Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
CN104958300B (zh) * 2013-11-03 2018-02-27 黑龙江福和华星制药集团股份有限公司 一种多索茶碱注射液
CN103788095A (zh) * 2014-01-20 2014-05-14 四川大学华西医院 2,4(1h,3h)-嘧啶二酮衍生物及其制备方法
WO2015134790A1 (en) * 2014-03-07 2015-09-11 Sanford-Burnham Medical Research Institute Small molecule fatty acid synthase inhibitors
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
EP3193880B1 (en) * 2014-09-19 2020-03-25 Eli Lilly and Company Inhibiting the transient receptor potential a1 ion channel
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
JP6788476B2 (ja) 2016-10-21 2020-11-25 株式会社ミツトヨ クロマティック共焦点センサ及び測定方法
US20190374552A1 (en) * 2016-11-02 2019-12-12 George Edward Hoag Multifunctional formulations and methods to control dermatitis and pruritus
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
CA3088551C (en) 2018-01-31 2023-01-24 Eli Lilly And Company Inhibiting the transient receptor potential a1 ion channel
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN108997350B (zh) * 2018-07-03 2021-03-02 南昌立德生物技术有限公司 一种周期蛋白依赖性激酶8抑制剂
US11377422B2 (en) 2019-03-11 2022-07-05 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3129089A1 (en) 2019-03-11 2020-09-17 Bridget Mccarthy Cole Ester substituted ion channel blockers and methods for use
CN113811305A (zh) 2019-03-11 2021-12-17 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
CN110343759A (zh) * 2019-06-03 2019-10-18 张鹏 Trpv4的用途及其抑制剂的用途和药物筛选方法
CN110526878A (zh) * 2019-09-16 2019-12-03 成都睿智化学研究有限公司 一种2-(噁唑基)乙胺的制备方法
CN112691094B (zh) * 2019-10-22 2022-09-23 中国科学院分子细胞科学卓越创新中心 防治病毒的新型化合物及其应用
CA3155568A1 (en) 2019-11-06 2021-05-14 Bridget Mccarthy Cole Charged ion channel blockers and methods for use
AU2020380118B2 (en) 2019-11-06 2026-06-11 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11332446B2 (en) 2020-03-11 2022-05-17 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US11744878B2 (en) 2020-08-19 2023-09-05 Chirhoclin, Inc. Methods for treatment of COVID-19 syndrome
MX2023003443A (es) * 2020-09-24 2023-06-22 Shanghai Yao Yuan Biotechnology Co Ltd Inhibidores de la proteína cinasa alfa 1 y métodos de uso.
CA3211048A1 (en) * 2021-04-14 2022-10-20 Boehringer Ingelheim International Gmbh 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors
CN118103045A (zh) 2021-04-19 2024-05-28 上海药苑生物科技有限公司 用于治疗川崎病的α蛋白激酶1抑制剂
EP4079304A1 (en) * 2021-04-21 2022-10-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Compounds for use in the treatment of hyperproliferative disorders
CN115477626B (zh) * 2021-06-16 2024-08-02 上海璃道医药科技有限公司 N-取代苯基磺酰胺类化合物及其用途
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
US11951082B2 (en) 2022-08-22 2024-04-09 Ford Therapeutics, Llc Composition of chlorhexidine
CN117986195A (zh) * 2023-01-10 2024-05-07 四川大学 一种新型杂环化合物及其制备方法和用途
CN116655635B (zh) * 2023-05-19 2024-01-26 济南爱思医药科技有限公司 黑茶茶碱衍生物及在制备药物中的应用
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599337A (en) * 1977-08-09 1986-07-08 Eisai Co., Ltd. Antiphlogistic/antipyretic/analgesic agents containing theobromine or theophylline derivatives as active ingredient
US4426383A (en) 1980-09-04 1984-01-17 Eisai Co., Ltd. Theophylline and theobromine derivatives
DE3364234D1 (en) * 1982-03-02 1986-07-31 Eisai Co Ltd Antiphlogistic/antipyretic/analgesic pharmaceutical compositions containing theophylline derivatives as active ingredient
HU190377B (en) * 1982-03-12 1986-08-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing theophyllinyl-alkyl-oxadiazoles
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
GB9524812D0 (en) 1995-12-05 1996-02-07 Leo Pharm Prod Ltd Chemical compounds
FR2761068B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
US20030199693A1 (en) * 2000-07-28 2003-10-23 Ing-Jun Chen Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activies on PDE-5 phosphodiesterase
US7818808B1 (en) 2000-12-27 2010-10-19 Intel Corporation Processor mode for limiting the operation of guest software running on a virtual machine supported by a virtual machine monitor
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
MXPA03008967A (es) 2002-02-01 2004-02-12 King Pharmaceuticals Res & Dev Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b.
JP2005525112A (ja) 2002-02-28 2005-08-25 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ジアシルグリセロールキナーゼεを使用して疼痛を処置する際の方法および組成物
GB0213869D0 (en) * 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
US20050209243A1 (en) * 2002-09-27 2005-09-22 Ing-Jun Chen Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
KR20060129411A (ko) 2004-03-30 2006-12-15 패러다임 테라퓨틱스 리미티드 이온 채널
KR101111099B1 (ko) 2004-09-09 2012-02-17 아바야 테크놀러지 코퍼레이션 네트워크 트래픽 보안 방법들 및 시스템들
US20070021992A1 (en) * 2005-07-19 2007-01-25 Srinivas Konakalla Method and system for generating a business intelligence system based on individual life cycles within a business process
WO2007054480A1 (en) * 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
EP1962855B1 (en) * 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
WO2007125405A2 (en) * 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009140519A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries

Also Published As

Publication number Publication date
CN101801362B (zh) 2014-01-22
AU2008268463A1 (en) 2008-12-31
JP6258266B2 (ja) 2018-01-10
US20130059869A1 (en) 2013-03-07
CN108042542A (zh) 2018-05-18
EP3663295A1 (en) 2020-06-10
EP2170309A1 (en) 2010-04-07
EP2170309A4 (en) 2010-11-03
JP2019147808A (ja) 2019-09-05
WO2009002933A1 (en) 2008-12-31
CN103751194B (zh) 2018-01-05
US20180133170A1 (en) 2018-05-17
CN101801362A (zh) 2010-08-11
CA2691468C (en) 2017-05-09
JP2017165790A (ja) 2017-09-21
HRP20200357T1 (hr) 2020-06-12
CA2691468A1 (en) 2008-12-31
JP2015180700A (ja) 2015-10-15
EP3184527A1 (en) 2017-06-28
US8163761B2 (en) 2012-04-24
JP2010530901A (ja) 2010-09-16
SI3184527T1 (sl) 2020-03-31
US20090143377A1 (en) 2009-06-04
EP3184527B1 (en) 2020-01-29
CN104825457B (zh) 2019-11-19
AU2008268463A2 (en) 2010-02-25
AU2008268463B2 (en) 2015-03-05
CA2962043A1 (en) 2008-12-31
CN103751194A (zh) 2014-04-30
EP2170309B1 (en) 2016-10-26
JP5932883B2 (ja) 2016-06-08
CN104825457A (zh) 2015-08-12
DK2170309T3 (en) 2017-01-09
JP2014141535A (ja) 2014-08-07

Similar Documents

Publication Publication Date Title
ES2436225T3 (es) Inhibidores TRPA1 para tratamiento del dolor
AU2008268463B2 (en) Methods and compositions for treating disorders
US8389546B2 (en) Compounds for modulating TRPV3 function
JP2010530901A5 (enExample)
AU2015202546B2 (en) Methods and Compositions for Treating Disorders
HK1240581A1 (en) 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
HK1240581B (en) 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
HK1142541B (en) 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
HK1142541A (en) 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
JP2012533605A (ja) 神経セロイドリポフスチン症の治療における使用のための１ｈ−キナゾリン−２，４−ジオン